Picato and Methotrexate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Picato (ingenol mebutate) and Methotrexate (methotrexate sodium). Common drug interactions include application site erythema among females and application site erythema among males.

The phase IV clinical study analyzes what interactions people have when they take Picato and Methotrexate. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Picato?

Picato has active ingredients of ingenol mebutate. eHealthMe is studying from 5,498 Picato users. Check the latest studies of Picato.

What is Methotrexate?

Methotrexate has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 604,313 Methotrexate users. Check the latest studies of Methotrexate.

On Aug, 07, 2026

13 people who take Picato and Methotrexate together, and have interactions are studied.

Picato and Methotrexate drug interactions.

What are the common drug interactions of Picato and Methotrexate, by gender? *:

female:

Application site erythema (redness of the skin at application site)
Application site discharge
Application site exfoliation (application site removal of the oldest dead skin cells on the skin's outermost surface)
Application site irritation
Application site pain
Application site scab (hard coating on the skin formed at application site)
Application site swelling
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
Erythema (redness of the skin)

male:

Application site erythema (redness of the skin at application site)

What are the common drug interactions of Picato and Methotrexate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Application site erythema (redness of the skin at application site)
Application site vesicles (small bubble within a cell at application site)
Drug administration error

60+:

Application site erythema (redness of the skin at application site)
Actinic keratosis (skin disease due to sun exposure)
Application site irritation
Application site pain
Application site scab (hard coating on the skin formed at application site)
Application site swelling
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
Erythema (redness of the skin)
Hyperkeratosis (thickening of the outer layer of the skin)

What are the existing conditions these people have? *

Actinic Keratosis (skin disease due to sun exposure): 7 people, 53.85%
Psoriasis (immune-mediated disease that affects the skin): 4 people, 30.77%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 1 person, 7.69%
Precancerous Skin Lesion: 1 person, 7.69%
Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 1 person, 7.69%
Allergic Granulomatous Angiitis (allergic inflammation of a blood vessel or lymph duct): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Picato and Methotrexate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously